Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 109Terminated 26Recruiting 21Active not recruiting 14Withdrawn 5Unknown 3Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 5Small Cell Lung Carcinoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, Follicular 2Glioma 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1TNBC 1Stomatitis 1Stomach Neoplasms 1Squamous Intraepithelial Lesions 1Smoldering Multiple Myeloma 1Recurrence 1Parkinsonian Disorders 1Pancreatic Neoplasms 1Pancreatic Cancer Non-resectable 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Nasopharyngeal Neoplasms 1

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Enrolling by invitation × Leukemia, Myelomonocytic, Chronic × Clear all
NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Taiho Oncology, Inc.

Phase 2 Enrolling by invitation
332 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡